About
Renibus Therapeutics is a clinical-stage biopharmaceutical company developing therapies to prevent disease progression, improve outcomes, and protect against organ damage in cardio, renal, and metabolic diseases, with multiple assets in clinical trials including the Phase 3 candidate Veverimer.
Explore Renibus Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.